These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2665758)

  • 1. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
    Kajikawa N; Nogimori K; Murata T; Nishio S; Uchiyama S
    Arzneimittelforschung; 1989 Apr; 39(4):495-9. PubMed ID: 2665758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
    Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T
    Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats.
    Umetsu T; Murata T; Nishio S
    Arzneimittelforschung; 1989 Jan; 39(1):68-73. PubMed ID: 2541730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets.
    Eggerman TL; Andersen NH; Robertson RP
    J Pharmacol Exp Ther; 1986 Mar; 236(3):568-73. PubMed ID: 2869139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli.
    Nishio S; Yamada N; Endoh T; Isogaya M; Fukatsu Y; Nishimura S; Kanai N; Umetsu T
    Arzneimittelforschung; 1989 Oct; 39(10):1229-34. PubMed ID: 2514691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits.
    Murai T; Muraoka K; Saga K; Sakai A; Sato N; Amemiya K; Yajima M; Murata T; Umetsu T; Nishio S
    Arzneimittelforschung; 1989 Aug; 39(8):856-9. PubMed ID: 2510741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
    Hirasawa Y; Nishio M; Maeda K; Yoshida K; Kita Y
    Eur J Pharmacol; 1995 Jan; 272(1):39-43. PubMed ID: 7713147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
    Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
    J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human prostacyclin platelet receptors and platelet lipid composition.
    Modesti PA; Abbate R; Prisco D; Gensini GF
    J Lipid Mediat; 1990; 2(6):309-15. PubMed ID: 2133274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
    Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
    Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
    Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
    Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1979 Jul; 210(1):134-40. PubMed ID: 221643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective binding site for [3H]prostacyclin on platelets.
    Siegl AM; Smith JB; Silver MJ; Nicolaou KC; Ahern D
    J Clin Invest; 1979 Feb; 63(2):215-20. PubMed ID: 372237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor.
    Virgolini I; Li S; Sillaber C; Majdic O; Sinzinger H; Lechner K; Bettelheim P; Valent P
    J Biol Chem; 1992 Jun; 267(18):12700-8. PubMed ID: 1377673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.